Good evening :)
Place Order
Add to Watchlist

Dishman Carbogen Amcis Ltd

DCAL Share Price

256.402.66% (+6.65)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹3,915 cr, stock is ranked 866

Stock is 4.38x as volatile as Nifty

DCAL Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

With a market cap of ₹3,915 cr, stock is ranked 866

Stock is 4.38x as volatile as Nifty

DCAL Performance & Key Metrics

DCAL Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
1,208.540.70
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
37.436.450.80%

DCAL Analyst Ratings & Forecast

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

DCAL Company Profile

Dishman Carbogen Amicis Limited is an India-based contract research and manufacturing services (CRAMS) company. The Company is engaged in the process of research and development to late-stage clinical and commercial manufacturing

Investor Presentation

View older View older 

May 22, 2025

PDF
View Older Presentations

DCAL Similar Stocks (Peers)

Compare with peers Compare with peers 

DCAL Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
82.13
82.13
1Y Return
48.40%
48.40%
Buy Reco %
50.00
50.00
PE Ratio
51.52
51.52
1Y Return
11.98%
11.98%
Buy Reco %
71.43
71.43
PE Ratio
31.04
31.04
1Y Return
55.67%
55.67%
Buy Reco %
0.00
0.00
PE Ratio
29.77
29.77
1Y Return
80.96%
80.96%
Buy Reco %
0.00
0.00
PE Ratio
-45.70
-45.70
1Y Return
91.50%
91.50%
Buy Reco %
0.00
0.00
Compare with Peers

DCAL Sentiment Analysis

DCAL Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

DCAL Stock Summary · May 2025

The company demonstrated robust financial performance, achieving a 9.4% revenue increase and significant EBITDA growth, driven by effective cost management and operational efficiencies. With a strong development pipeline and successful operational advancements, particularly in France and China, the firm is well-positioned for future growth, despite facing challenges such as rising raw material costs and currency fluctuations. Strategic investments in digital transformation and enhanced collaboration across regions are expected to bolster profitability and operational effectiveness. While navigating project viability concerns and increasing trade receivables, management remains optimistic about maintaining strong client relationships and achieving ambitious targets for revenue and return on capital employed. Overall, the outlook reflects a balanced approach to growth and financial health.

DCAL Stock Growth Drivers
DCAL Stock Growth Drivers
8
  • Strong Financial Performance

    The company reported significant financial achievements, including a 9.4% increase in revenue from operations for

  • Operational Advancements and Capacity Expansion

    The company achieved operational milestones, particularly with its French facility, which is now fully operational

DCAL Stock Challenges
DCAL Stock Challenges
7
  • Declining Revenue in Specific Segments

    The Cholesterol and Vitamin D analogues business reported a decrease in revenue, generating INR 305

  • High Inventory Levels

    The company reported high inventory days ranging from 550 to 650 days, attributed to the

DCAL Forecast

DCAL Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

DCAL

DCAL

Income

Balance Sheet

Cash Flow

DCAL Income Statement

DCAL Income Statement

Industry refers to the sub-sector this company belongs to.
Lower than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 5.53%, vs industry avg of 7.5%

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 17.14% to 13.78%

Lower than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of -54.07%, vs industry avg of 8.25%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue1,739.821,740.482,112.422,088.061,950.482,184.112,440.692,643.982,733.182,735.22
Raw Materialssubtract329.58402.19378.01476.38434.77460.50630.40601.212,260.672,262.71
Power & Fuel Costsubtract49.4748.3356.1460.2641.8762.7387.83104.31
Employee Costsubtract596.02625.40714.64762.27872.91981.491,029.861,208.16
Selling & Administrative Expensessubtract147.69136.29190.73124.58113.81147.71197.66205.53
Operating & Other expensessubtract138.4737.23167.18122.55196.60171.53183.12216.20
Depreciation/Amortizationsubtract213.50211.42240.38282.87307.94307.59280.72310.86293.74293.74
Interest & Other Itemssubtract49.0148.8356.5561.9547.6156.8185.69119.97159.46159.46
Taxes & Other Itemssubtract70.6576.2298.4638.69100.10-22.26-24.7931.1916.0716.07
EPS19.1513.039.96-10.531.15-1.90-9.790.210.21
DPS1.200.000.200.000.000.000.000.000.000.00
Payout ratio0.000.020.000.000.000.000.000.000.00

DCAL Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual Report Pending

Investor Presentation

May 22PDF
Feb 12PDF
Nov 13PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 23PDF
Feb 10PDF
Nov 11PDF
Aug 9PDF
FY 2022FY 2022

Annual report

PDF

Investor Presentation

May 11PDF
Feb 4PDF
Oct 28PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
 

DCAL Stock Peers

DCAL Past Performance & Peer Comparison

DCAL Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareLabs & Life Sciences Services

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Dishman Carbogen Amcis Ltd1,208.540.70
Divi's Laboratories Ltd82.1313.260.44%
Syngene International Ltd51.525.410.20%
Aarti Pharmalabs Ltd31.044.810.54%

DCAL Stock Price Comparison

Compare DCAL with any stock or ETF
Compare DCAL with any stock or ETF
DCAL
Loading...

DCAL Holdings

DCAL Shareholdings

DCAL Promoter Holdings Trend

DCAL Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

DCAL Institutional Holdings Trend

DCAL Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

DCAL Shareholding Pattern

DCAL Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding59.32%1.06%0.20%9.49%29.93%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

DCAL Shareholding History

DCAL Shareholding History

Dec '23MarJunSepDec '24Mar8.61%8.70%8.04%8.17%8.75%9.49%

Mutual Funds Invested in DCAL

Mutual Funds Invested in DCAL

No mutual funds holding trends are available

Top 5 Mutual Funds holding Dishman Carbogen Amcis Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.9460%0.72%0.01%70/89 (-32)
0.1317%0.21%-0.00%205/255 (-6)
0.0006%0.01%0.00%463/755 (-3)

Compare 3-month MF holding change on Screener

DCAL Insider Trades & Bulk Stock Deals

DCAL Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing DCAL stock

smallcases containing DCAL stock

Looks like this stock is not in any smallcase yet.

DCAL Events

DCAL Events

DCAL Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

DCAL has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

DCAL Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

DCAL has not given any dividends in last 5 years

DCAL Upcoming Dividends

DCAL Upcoming Dividends

No upcoming dividends are available

DCAL Past Dividends

DCAL Past Dividends

Cash Dividend

Ex DateEx DateSep 12, 2019

Final
Final | Div/Share: ₹0.20

Dividend/Share

0.20

Ex DateEx Date

Sep 12, 2019

DCAL Stock News & Opinions

DCAL Stock News & Opinions

Spotlight
Dishman Carbogen Amcis' Ahmedabad facility clears USFDA inspection without observations

The inspection was conducted from 9 June to 13 June 2025. According to the company's statement, the audit concluded without any observations or the issuance of a Form 483, indicating that the USFDA found no procedural or compliance-related concerns during the inspection. As a result, the company's facilities at Naroda and Bavla in India, along with multiple group facilities in Switzerland and the Netherlands, continue to maintain USFDA approval. The official announcement was made on Saturday, 14 June 2025. Dishman Carbogen Amcis is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. It provides a range of development and manufacturing solutions at locations in Europe, China and in India. The company reported a consolidated net profit of Rs 43.09 crore in Q4 March 2025 as against a net loss of Rs 69.92 crore in Q4 March 2024. Revenue from operations rose 9.41% year-on-year to Rs 716.34 crore in Q4 March 2025. The counter declined 2.29% to Rs 273.05 on the BSE. Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Carbogen Amic AG to co-invest in its manufacturing sites in Switzerland

Dishman Carbogen Amcis' wholly owned subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland. The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including: ' Aarau site: installation of 850-litre reactors and 0.4 m' agitated filter dryers with supporting equipment. Completion is expected by Q1 2027. ' Neuland site: installation of 850-litre reactors and 0.4 m' agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027. This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Dishman Carbogen spurts after turnaround Q4 outcome

Consolidated net sales rose 9.41% year-on-year to Rs 716.34 crore in Q4 March 2025. Pre-tax profit before exxceptional items stood at Rs 39.45 crore in Q4 FY25 as against pre-tax loss before exceptional items of Rs 46.11 crore in Q4 FY24. For the full year, the company reported net profit of Rs 3.24 crore in the year ended March 2025 as against net loss of Rs 153.45 crore in the year ended March 2024. Net sales rose 3.66% YoY to Rs 2711.50 crore in the year ended March 2025. Pre-tax profit before exceptional items stood at Rs 37.42 crore in FY25 as against pre-tax loss before exceptional items of Rs 116.12 crore in FY24. During the quarter and year ended 31 March 2025, certain subsidiaries discarded some of their inventories, which was not expected to be usable for projects that the company estimated to undertake in near to mid-term. The loss on account of these impairment were Rs 0.77 crore and Rs 7.13 crore respectively for the quarter and year. Further, during the quarter ended 31 March 2025, one of the subsidiaries Carbogen Amcis AG, had impaired expenditure incurred for capex project. The loss on account of this impairment was Rs 10.98 crore for the quarter and the year. The company's consolidated net cash from operating activities stood at Rs 375.23 crore in FY25, lower than Rs 379.43 crore in FY24. Dishman Carbogen Amcis is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. It provides a range of development and manufacturing solutions at locations in Europe, China and in India. Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Dishman Carbogen Amcis reports consolidated net profit of Rs 43.09 crore in the March 2025 quarter

Net profit of Dishman Carbogen Amcis reported to Rs 43.09 crore in the quarter ended March 2025 as against net loss of Rs 69.92 crore during the previous quarter ended March 2024. Sales rose 9.41% to Rs 716.34 crore in the quarter ended March 2025 as against Rs 654.71 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 3.24 crore in the year ended March 2025 as against net loss of Rs 153.45 crore during the previous year ended March 2024. Sales rose 3.66% to Rs 2711.50 crore in the year ended March 2025 as against Rs 2615.77 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales716.34654.71 9 2711.502615.77 4 OPM %21.329.57 -17.2910.95 - PBDT118.5438.89 205 331.16194.74 70 PBT39.45-46.11 LP 37.42-116.12 LP NP43.09-69.92 LP 3.24-153.45 LP Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Dishman Carbogen Amcis reports standalone net loss of Rs 7.37 crore in the March 2025 quarter

Net Loss of Dishman Carbogen Amcis reported to Rs 7.37 crore in the quarter ended March 2025 as against net loss of Rs 31.12 crore during the previous quarter ended March 2024. Sales declined 4.64% to Rs 106.10 crore in the quarter ended March 2025 as against Rs 111.26 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 9.87 crore in the year ended March 2025 as against net loss of Rs 76.41 crore during the previous year ended March 2024. Sales rose 22.14% to Rs 399.84 crore in the year ended March 2025 as against Rs 327.35 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales106.10111.26 -5 399.84327.35 22 OPM %19.3510.40 -17.952.08 - PBDT4.69-7.51 LP 34.371.66 1970 PBT-11.41-33.63 66 -30.83-99.95 69 NP-7.37-31.12 76 -9.87-76.41 87 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Dishman Carbogen Amcis to hold board meeting

Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 21 May 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Dishman Carbogen Amcis' Shanghai facility clears China regulatory compliance

Dishman Carbogen Amcis announced that its Shanghai facility has successfully obtained its first Drug Manufacturing License (DML) from China's National Medical Products Administration (NMPA). The NMPA approval followed a rigorous review focused on GMP compliance and operational readiness. The Shanghai site successfully met all regulatory expectations, reflecting the maturing of its operations and the strength of its quality systems. This milestone marks a pivotal step in CARBOGEN AMCIS' expansion in China and reinforces its commitment to customers in the region. Located in the Shanghai Chemical Industry Park (SCIP), the 40,000m' site is a fully self-supporting facility equipped for early-phase research and development, pilot scale production and commercial GMP manufacture. Its services range from raw materials to APIs, including high potency material handling and micronization. With equipment in four segregated units and reactor capacities from 50 to 6,300 litres, the facility is built for flexibility, efficiency and scalability. The site employs over 140 people and brings together an international team of specialists whose expertise, combined with advanced infrastructure, enables the delivery of tailored, scalable solutions to customers worldwide. Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Dishman Carbogen Amcis receives affirmation in credit ratings

Dishman Carbogen Amcis has received affirmation in credit ratings from India Ratings and Research at IND A+; Stable/ IND A1+ for various debt facilities availed by the company. Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Dishman Carbogen Amcis allots NCDs aggregating Rs 50 cr

Dishman Carbogen Amcis has allotted 5,000 Rated, Listed, Senior, Secured, Redeemable, Taxable Non-Convertible Debentures of face value of Rs. 1,00,000 each, aggregating to Rs 50 crore on private placement basis. Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Dishman Carbogen Amcis to hold board meeting

Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 12 March 2025.Powered by Capital Market - Live

4 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Dishman Carbogen Amcis Ltd (DCAL) today?

    The share price of DCAL as on 15th July 2025 is ₹256.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Dishman Carbogen Amcis Ltd (DCAL) share?

    The past returns of Dishman Carbogen Amcis Ltd (DCAL) share are
    • Past 1 week: -7.29%
    • Past 1 month: -10.11%
    • Past 3 months: 22.17%
    • Past 6 months: 0.53%
    • Past 1 year: 52.83%
    • Past 3 years: 112.96%
    • Past 5 years: 62.28%

  3. What are the peers or stocks similar to Dishman Carbogen Amcis Ltd (DCAL)?
  4. What is the market cap of Dishman Carbogen Amcis Ltd (DCAL) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dishman Carbogen Amcis Ltd (DCAL) is ₹3915.66 Cr as of 15th July 2025.

  5. What is the 52 week high and low of Dishman Carbogen Amcis Ltd (DCAL) share?

    The 52-week high of Dishman Carbogen Amcis Ltd (DCAL) is ₹307.98 and the 52-week low is ₹155.05.

  6. What is the PE and PB ratio of Dishman Carbogen Amcis Ltd (DCAL) stock?

    The P/E (price-to-earnings) ratio of Dishman Carbogen Amcis Ltd (DCAL) is 1208.54. The P/B (price-to-book) ratio is 0.70.

  7. Which sector does Dishman Carbogen Amcis Ltd (DCAL) belong to?

    Dishman Carbogen Amcis Ltd (DCAL) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.

  8. How to buy Dishman Carbogen Amcis Ltd (DCAL) shares?

    You can directly buy Dishman Carbogen Amcis Ltd (DCAL) shares on Tickertape. Simply sign up, connect your demat account and place your order.